Impact of organ dysfunction on mortality in ICU patients with hematologic malignancies

被引:28
作者
Vandijck, Dominique M. [1 ,2 ]
Depuydt, Pieter O. [3 ]
Offner, Fritz C. [4 ]
Nollet, Joke [3 ]
Peleman, Renaat A. [2 ]
Steel, Eva [4 ]
Noens, Lucien A. [4 ]
Decruyenaere, Johan M. [3 ]
Benoit, Dominique D. [3 ]
机构
[1] Univ Ghent, Dept Publ Hlth & Hlth Econ, Fac Med & Hlth Sci, B-9000 Ghent, Belgium
[2] Ghent Univ Hosp, Dept Gen Internal Med & Infect Dis, B-9000 Ghent, Belgium
[3] Ghent Univ Hosp, Dept Intens Care Med, B-9000 Ghent, Belgium
[4] Ghent Univ Hosp, Dept Hematol, B-9000 Ghent, Belgium
关键词
Admission diagnosis; Critically ill; Evolution; Hematologic malignancy; Outcome; Sequential Organ Failure Assessment score; INTENSIVE-CARE-UNIT; RECENT INTRAVENOUS CHEMOTHERAPY; SEPTIC SHOCK PATIENTS; CANCER-PATIENTS; RESPIRATORY-FAILURE; PROGNOSTIC-FACTORS; SEVERE SEPSIS; ILL PATIENTS; ADMISSION; MULTICENTER;
D O I
10.1007/s00134-010-1903-8
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
To compare evolution in organ dysfunction (OD) between hematologic malignancy patients with and without bacterial infection (BI) precipitating intensive care unit (ICU) admission, and to assess its impact on mortality. Retrospective analysis of prospectively collected data was performed. Sequential Organ Failure Assessment (SOFA) scores from day 1 to 5 were calculated in all consecutive hematologic malignancy patients admitted to the ICU (2000-2006). Patients were categorized according to the presence or absence, the diagnostic certainty, and the site of BI. Of the 344 patients admitted, 258 were still in the ICU at day 3 and 164 at day 5. Patients admitted because of BI had more severe OD on day 1 (SOFA 9.7 +/- A 4.0 vs. 8.4 +/- A 4.0, p = 0.008) but a more rapidly reversible OD within the first 3 days (Delta SOFA -1.12 +/- A 3.10 vs. 0.03 +/- A 3.40, p = 0.013) and a lower in-hospital (43.2% vs. 62.9%, p < 0.001) and 6-month mortality (52.1% vs. 71.7%, p < 0.001) than patients with other complications. In a multivariate analysis, BI remained associated with a lower risk of death (OR 0.20, 95% CI 0.1-0.4, p < 0.001) even after adjustment for the SOFA on day 1 (OR 1.36, 95% CI 1.22-1.52, p < 0.001) and the Delta SOFA (OR 1.48, 95% CI 1.29-1.68, p < 0.001). These findings remained significant regardless of the site and the diagnostic certainty of BI. BI is associated with a more severe initial but a more rapidly reversible OD and a subsequent lower mortality compared to other complications in ICU patients with hematologic malignancies. These findings further support the recommendation that these patients should certainly benefit from advanced life support, and in the case of an uncertain long-term prognosis due to the underlying malignancy, at least from a 3-day ICU trial.
引用
收藏
页码:1744 / 1750
页数:7
相关论文
共 50 条
  • [21] Hyperglycemia in Patients with Hematologic Malignancies
    Sara J. Healy
    Kathleen M. Dungan
    [J]. Current Diabetes Reports, 2015, 15
  • [22] Bacteremia in patients with hematologic malignancies
    Wang, FD
    Liu, YM
    Liu, CY
    [J]. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 1998, 97 (06) : 405 - 409
  • [23] Cholecystectomy in patients with hematologic malignancies
    Stewart, Camille L.
    Tran, Thuy B.
    Nguyen, Andrew
    Zain, Jasmine
    Lai, Lily
    Fong, Yuman
    Woo, Yanghee
    [J]. AMERICAN JOURNAL OF SURGERY, 2022, 223 (06) : 1157 - 1161
  • [24] Evaluation of the logistic organ dysfunction system for the assessment of organ dysfunction and mortality in critically ill patients
    Metnitz, PGH
    Lang, T
    Valentin, A
    Steltzer, H
    Krenn, CG
    Le Gall, JR
    [J]. INTENSIVE CARE MEDICINE, 2001, 27 (06) : 992 - 998
  • [25] Development and Validation of a Prediction Model for 1-Year Mortality in Patients With a Hematologic Malignancy Admitted to the ICU
    Boldingh, Jan-Willem H. L.
    Arbous, M. Sesmu
    Biemond, Bart J.
    Blijlevens, Nicole M. A.
    van Bommel, Jasper
    Hilkens, Murielle G. E. C.
    Kusadasi, Nuray
    Muller, Marcella C. A.
    de Vries, Vera A.
    Steyerberg, Ewout W.
    van den Bergh, Walter M.
    [J]. CRITICAL CARE EXPLORATIONS, 2024, 6 (06)
  • [26] Prevalence of acute liver dysfunction and impact on outcome in critically ill patients with hematological malignancies: a single-center retrospective cohort study
    Van de Louw, Andry
    Twomey, Kathleen
    Habecker, Nicholas
    Rakszawski, Kevin
    [J]. ANNALS OF HEMATOLOGY, 2021, 100 (01) : 229 - 237
  • [27] Pseudomonas aeruginosa bacteraemia in patients with hematologic malignancies: risk factors, treatment and outcome
    Tofas, Polydoros
    Samarkos, Michael
    Piperaki, Evangelia-Theophano
    Kosmidis, Christos
    Triantafyllopoulou, Ioanna-Dionysia
    Kotsopoulou, Maria
    Pantazatou, Aggeliki
    Perlorentzou, Stavroula
    Poulli, Anastasia
    Vagia, Maria
    Daikos, George L.
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2017, 88 (04) : 335 - 341
  • [28] Characteristics and outcomes of patients with hematologic malignancies receiving chemotherapy in the intensive care unit
    Pastores, Stephen M.
    Goldman, Debra A.
    Shaz, David J.
    Kostelecky, Natalie
    Daley, Ryan J.
    Peterson, Tim J.
    Tan, Kay See
    Halpern, Neil A.
    [J]. CANCER, 2018, 124 (14) : 3025 - 3036
  • [29] Pulmonary disease in patients with hematologic malignancies
    Poletti, V
    Trisolini, R
    Tura, S
    [J]. SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2002, 19 (01) : 29 - 45
  • [30] The Association of the Lactate-Albumin Ratio With Mortality and Multiple Organ Dysfunction in PICU Patients
    Ray, Christopher C.
    Pollack, Murray M.
    Gai, Jiaxiang
    Patel, Anita K.
    [J]. PEDIATRIC CRITICAL CARE MEDICINE, 2023, 24 (09) : 760 - 766